Results 1 to 10 of about 538,544 (149)

The effect of COVID-19 emergency in the management of melanoma in Italy

Dermatology Reports, 2021
The COVID-19 pandemic has severely hampered the functioning of any health system, absorbing a considerable amount of resources and with the threat of widespread infection in the health services.
Intergruppo Melanoma Italiano
doaj   +1 more source

XXVI IMI National Congress - 1st virtual edition | 7-9 November 2020

Dermatology Reports, 2021
s from the XXVI IMI National Congress (virtual edition).
Italian Melanoma Intergroup (IMI)
doaj   +1 more source

XXVIII Italian Melanoma Intergroup National Congress - Florence, Italy | 30 September-2 October 2022

Dermatology Reports, 2023
s from the Italian Melanoma Intergroup (IMI) National ...
Italian Melanoma Intergroup (IMI)
doaj   +1 more source

Cross-platform comparison of immune signatures in immunotherapy-treated patients with advanced melanoma using a rank-based scoring approach

Journal of Translational Medicine, 2023
Background Gene expression profiling is increasingly being utilised as a diagnostic, prognostic and predictive tool for managing cancer patients. Single-sample scoring approach has been developed to alleviate instability of signature scores due to ...
Yizhe Mao, Tuba N. Gide, Nurudeen A. Adegoke, Camelia Quek, Nigel Maher, Alison Potter, Ellis Patrick, Robyn P. M. Saw, John F. Thompson, Andrew J. Spillane, Kerwin F. Shannon, Matteo S. Carlino, Serigne N. Lo, Alexander M. Menzies, Inês Pires da Silva, Georgina V. Long, Richard A. Scolyer, James S. Wilmott   +17 more
doaj   +1 more source

Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3 + anti-PD-1-based immunotherapies

OncoImmunology, 2023
Lymphocyte-activation gene-3 (LAG-3), an immune checkpoint receptor, negatively regulates T-cell function and facilitates immune escape of tumors. Dual inhibition of LAG-3 and programmed cell death receptor-1 (PD-1) significantly improved progression ...
Tuba N. Gide, Elizabeth C. Paver, Zarwa Yaseen, Nigel Maher, Nurudeen Adegoke, Alexander M. Menzies, Ines Pires da Silva, James S. Wilmott, Georgina V. Long, Richard A. Scolyer   +9 more
doaj   +1 more source

Lysine Demethylases: Promising Drug Targets in Melanoma and Other Cancers

Frontiers in Genetics, 2021
Epigenetic dysregulation has been implicated in a variety of pathological processes including carcinogenesis. A major group of enzymes that influence epigenetic modifications are lysine demethylases (KDMs) also known as “erasers” which remove methyl ...
Gaya Punnia-Moorthy, Gaya Punnia-Moorthy, Gaya Punnia-Moorthy, Peter Hersey, Peter Hersey, Abdullah Al Emran, Abdullah Al Emran, Jessamy Tiffen, Jessamy Tiffen, Jessamy Tiffen   +9 more
doaj   +1 more source

Demographic, Clinical, and Pathologic Features of Patients With Cutaneous Melanoma: Final Analysis of the Brazilian Melanoma Group Database

JCO Global Oncology, 2020
PURPOSE National epidemiologic data on melanoma are scarce in Brazil. The current work presents final demographic, clinical, and pathologic results from the Brazilian Melanoma Group database to detail how patients with melanoma present at diagnosis ...
Alberto Julius Alves Wainstein, João Pedreira Duprat Neto, Mauro Yoshiaki Enokihara, Eduard René Brechtbühl, Felice Riccardi, Gilles Landman, Andreia Cristina de Melo, Vinicius de Lima Vazquez, Rodrigo Ramella Munhoz, Ivan Dunshee De Abranches Oliveira Santos Filho, Eduardo Bertolli, Ana Paula Drummond-Lage, Bianca Costa Soares de Sá, Luciane Botelho, Jose Higino Steck, Francisco Aparecido Belfort, Marcus Maia, Renato Marchiori Bakos, Elimar Elias Gomes, Rafael Schmerling, Flavio Cavarsan   +20 more
doaj   +1 more source

Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition

Nature Communications, 2020
Transcriptomic signatures designed to predict melanoma patient responses to PD-1 blockade have been reported but rarely validated. We now show that intra-patient heterogeneity of tumor responses to PD-1 inhibition limit the predictive performance of ...
Jenny H. Lee, Elena Shklovskaya, Su Yin Lim, Matteo S. Carlino, Alexander M. Menzies, Ashleigh Stewart, Bernadette Pedersen, Malama Irvine, Sara Alavi, Jean Y. H. Yang, Dario Strbenac, Robyn P. M. Saw, John F. Thompson, James S. Wilmott, Richard A. Scolyer, Georgina V. Long, Richard F. Kefford, Helen Rizos   +17 more
doaj   +1 more source

Classification of the tumor immune microenvironment and associations with outcomes in patients with metastatic melanoma treated with immunotherapies

Journal for ImmunoTherapy of Cancer, 2023
Background Tumor microenvironment (TME) characteristics are potential biomarkers of response to immune checkpoint inhibitors in metastatic melanoma.
Ines Pires da Silva, Richard A Scolyer, Georgina Long, Matteo S Carlino, Ismael A Vergara, James S Wilmott, Serigne N Lo, Tuba N Gide, Alexander Maxwell Menzies, Nurudeen A Adegoke, Yizhe Mao, Camelia Quek, Ellis Patrick   +12 more
doaj   +1 more source

The efficacy of anti‐programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma

Cancer Medicine, 2021
Background Anti‐programmed cell death protein 1 (PD‐1) antibodies are a standard treatment for metastatic melanoma patients. However, the understanding of the efficacy of anti‐PD‐1 for acral melanoma (AM) and mucosal melanoma (MM) is limited as these ...
Dai Ogata, Lauren E. Haydu, Isabella C. Glitza, Sapna P. Patel, Hussein A. Tawbi, Jennifer L. McQuade, Adi Diab, Suhendan Ekmekcioglu, Michael K. Wong, Michael A. Davies, Rodabe N. Amaria   +10 more
doaj   +1 more source